Exicure, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00GTJCSB4
XCUR
Exicure, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Exicure, Inc.
ISIN
US30205M2008
TICKER
XCUR
MIC
XNAS
REUTERS
XCUR.OQ
BLOOMBERG
XCUR US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 14.11.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, the "Company") has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and dev...
Exicure
Wed, 18.09.2024
Exicure
US30205M2008
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Mark...
Exicure
Tue, 10.09.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the “Court”). The settlement i...
Exicure
Mon, 26.08.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjust...
Exicure
Mon, 19.08.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting"), initially scheduled for August 15, 2024 and adjourned and reconvened on August 19, 2024, has been adjourned again for the purpose of soliciting additional votes with respect to the proposal described in the Company's defini...
Exicure
Thu, 15.08.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, the "Company") announced today that its Special Meeting of Stockholders (the "Special Meeting") scheduled for and convened on August 15, 2024 has been adjourned for the purpose of soliciting additional votes with respect to the proposal described in the Company's definitive proxy statement for the Special Meeting filed...
Exicure
Tue, 13.08.2024
Exicure
US30205M2008
Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and de...
Exicure
Thu, 08.08.2024
Exicure
US30205M2008
Anna Chukaeva has been appointed as Senior Vice President, Head of Corporate Development and Bioinformatics of Exicure, Inc. (“the Company”) (Nasdaq: XCUR). Anna will spearhead investments, acquisitions, and strategic partnerships. She will also push into leveraging data and AI for drug discovery and diagnostics.
Anna was the co-founder, Preside...
Exicure
Information on product placements
